What is Xalkori?
Xalkori is a targeted therapy used to treat certain non-small cell lung cancers (NSCLCs) with certain lymphoma kinase (ALK) mutations.
ALK mutations are identified by biomarker tests (molecular tests) conducted on a biopsy specimen of the tumor.
Xalkori is an ALK inhibitor and is also classified as a tyrosine kinase inhibitor (TKI). It is designed to block the activating sites (tyrosine kinases) of certain proteins in cancer cells.
These proteins can stimulate cancer growth when the tumor has an ALK mutation. By blocking the proteins, Xalkori can shrink cancer or slow its progress.
Xalkori is used to treat patients with NSCLC who have a certain mutation in the ALK gene that has spread to other parts of the body (metastasized).
Xalkori is also used to treat patients with metastatic NSCLC who have the ROS1 mutation.
Active ingredient: Crizotinib 250mg.
Specification: Box of 60 tablets.
Origin: Pifzer
Registration number: Updating.
What does Xalkori do?
Xalkori contains the active ingredient crizotinib, a protein kinase inhibitor. The drug works by interfering with the signals that control the growth of cancer cells.
The way cells in the body function and grow is regulated by protein kinases. These enzymes can be found in several receptors on the surface of cells that are involved in the growth and spread of cancer cells.
In cancer cells, kinases cause cells to grow and multiply abnormally. They also stimulate nearby blood vessels to grow into tumors.
New blood vessels allow cancer cells to grow and multiply by providing them with oxygen and nutrients. Cancer cells spread to other areas of the body through blood circulation.
Xalkori Crizotinib works by blocking the action of an ALK enzyme. This kinase is overactive in certain types of lung cancer cells and it stimulates the growth and spread of cancer cells.
The overactive enzyme is caused by a defective gene in cancer cells. Crizotinib only works in non-small cell lung cancers with ALK mutations,
By blocking the action of ALK, Xalkori may slow or stop the growth of non-small cell lung cancer and may also shrink the tumor.
Dosage and how to take Xalkori?
The dose of XALKORI is 250 mg twice daily (500 mg daily) taken continuously.
If a dose is missed, it should be taken as soon as the patient remembers unless it is less than 6 hours until the next dose. In that case, the patient should not take the missed dose.
Patients should not take 2 doses at the same time to make up for a missed dose.
Dosage is determined by several factors, including the patient's general health, liver and kidney function, and ongoing response to treatment.
Patients should not drink grapefruit juice or eat grapefruit during treatment with Xalkori, as it may increase the level of Xalkori in the blood to harmful levels.2.
See more:
https://thuoclp.com/thuoc-ung-thu/ung-thu-phoi/thuoc-xalkori-250mg/
https://thuoclpvietnamese.business.site/posts/4352879590551145000
https://twitter.com/i/moments/1414587001190318081
https://www.pinterest.com/pin/721279696575842952/
https://issuu.com/thuoclp/docs/thuoclp-thuoc-xalkori-250mg-crizotinib-dieu-tri-un
https://www.vietnamta.vn/thuoclp/?link-id=121504
https://www.slideshare.net/ThuocLP/thuoc-xalkori-250mg-mua-o-dau-gia-bao-nhieu-thuoclp-vietnamese
https://getpocket.com/@bstranngocanh/share/6470372
Nhận xét
Đăng nhận xét